



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Eaton, et al.
Appl. No. : 10/063,534
Filed : May 2, 2002
For : ANTIBODIES TO A
POLYPEPTIDE ENCODED BY A
NUCLEIC ACID
OVEREXPRESSED IN KIDNEY
TUMOR AND
UNDEREXPRESSED IN LUNG
TUMOR (as amended)
Examiner : Seharaseyon, J.
Group Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 2, 2004

(Date)


AnneMarie Kaiser, Reg. No. 37,649

RESPONSE TO NOTICE TO COMPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Response to the Notice to Comply conforms the Sequence Listing to the rules of practice specified by the United States Patent and Trademark Office. Submitted herewith is a paper copy of the Sequence Listing and a copy of the Notice to Comply.

Please enter the attached sequence listing in the above-referenced application.

VERIFICATION UNDER 37 C.F.R. §1.821(f) & (g)

The sequences appearing in the attached Sequence Listing were included in the application as filed. Pursuant to 37 C.F.R. §1.821(g), no new matter is being added herewith. As required under 37 C.F.R. §1.821(f), I hereby verify that the data on the disk previously submitted and the paper copy of the Sequence Listing are identical.

Appl. No. : 10/063,534
Filed : May 2, 2002

Applicants believe this response to Notice to Comply brings the present application into compliance with the Sequence Listing requirements. A copy of the Notice to Comply is also submitted herewith.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,


KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Sept. 2, 2004

By: AnneMarie Kaiser
AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

S:\DOCS\BSG\BSG-1357.DOC
081304

COPY



Notice to Comply

Application No.

10/063 534

Applicant(s)

EATON ET AL

Examiner

J. Scheraga

Art Unit

1647

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

GenBank (Release 142, jun 2004)

494 100 0.0

P_AAF92072 Human PRO831 cDNA. 494 bp, cDNA, PAT 15-MAY-2001

ACCESSION P_AAF92072

KEYWORDS GENESEQ; Human; PRO protein; mapping; patent; patentdb (v200414, 01-JUL-2004).

SOURCE Homo sapiens.

ORGANISM Homo sapiens.

REFERENCE 1 (bases 1 to 494)

AUTHORS Eaton,D.L., Filvaroff,E., Gerritsen,M.E., Goddard,A.,
Godowski,P.J. Grimaldi,C.J., Gurney,A.L., Watanabe,C.K.,
Wood,W.I.

TITLE Eighty four nucleic acids encoding PRO polypeptides, useful in
molecular biology, including use as hybridization probes, and in
chromosome and gene mapping.

JOURNAL Patent: WO200116318-A2; Filing Date: 24-AUG-2000; 2000WO-US023328;
Publication Date: 08-MAR-2001; Priority: 01-SEP-1999;
99WO-US020111. 15-SEP-1999; 99WO-US021090. 07-DEC-1999;
99US-0169495P. 09-DEC-1999; 99US-0170262P. 11-JAN-2000;
2000US-0175481P. 18-FEB-2000; 2000WO-US004341. 18-FEB-2000;
2000WO-US004342. 22-FEB-2000; 2000WO-US004414. 01-MAR-2000;
2000WO-US005601. 03-MAR-2000; 2000US-0187202P. 21-MAR-2000;
2000US-0191007P. 30-MAR-2000; 2000WO-US008439. 25-APR-2000;
2000US-0199397P. 22-MAY-2000; 2000WO-US014042. 05-JUN-2000;
2000US-0209832P; Assignee: (GETH) GENENTECH INC; Cross Reference:
WPI; 2001-183260/18. P-PSDB; AAB87540; Patent Format: Claim 2; Fig
29; 278pp; English.

COMMENT The present sequence is the coding sequence for a human PRO
polypeptide (secreted and transmembrane). The PRO protein, and PRO
agonists, PRO antagonists or anti-PRO antibodies are useful for
preparation of a medicament useful in the treatment of a condition
which is responsive to the PRO protein, agonists, antagonists or
anti-PRO antibodies. The PRO protein may also be employed as
molecular weight markers for protein electrophoresis. The PRO
coding sequence has applications in molecular biology, including
use as hybridisation probes, and in chromosome and gene mapping

FEATURES Location/Qualifiers

BASE COUNT 128 a 111 c 120 g 135 t

ORIGIN

494 100 0.0

AX092298 Sequence 29 from Patent WO0116318. 494 bp,
DNA, linear, PAT 21-MAR-2001

ACCESSION AX092298

VERSION AX092298.1 GI:13444463

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Eaton,D.L., Filvaroff,E., Gerritsen,M.E., Goddard,A.,
Godowski,P.J., Grimaldi,C.J., Gurney,A.L., Watanabe,C.K. and
Wood,W.I.

TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same

JOURNAL Patent: WO 0116318-A 29 08-MAR-2001;
Genentech, Inc. (US)

FEATURES Location/Qualifiers
source 1..494
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

BASE COUNT
ORIGIN

493 100 0.0
P_AAA37028 Human PRO831 (UNQ471) cDNA sequence SEQ ID NO:21. 493 bp,
cDNA, PAT 08-AUG-2000

ACCESSION P_AAA37028

KEYWORDS GENESEQ; Human; PRO polypeptide; membrane bound protein; receptor;
diagnosis; transmembrane; secretion; immunoadhesion; pharmaceutical;
screening; patent; patentdb (v200414, 01-JUL-2004).

SOURCE Homo sapiens.
ORGANISM Homo sapiens.

REFERENCE 1 (bases 1 to 493)
AUTHORS Baker,K., Goddard,A., Gurney,A.L., Smith,V., Watanabe,C.K.,
Wood,W.I.

TITLE New mammalian DNA sequences encoding transmembrane, receptor or
secreted PRO polypeptides, useful for screening of potential
peptide or small molecule inhibitors of the relevant
receptor/ligand interactions.

JOURNAL Patent: WO200012708-A2; Filing Date: 01-SEP-1999; 99WO-US020111;
Publication Date: 09-MAR-2000; Priority: 01-SEP-1998;
98US-0098716P. 01-SEP-1998; 98US-0098749P. 01-SEP-1998;
98US-0098750P. 02-SEP-1998; 98US-0098803P. 02-SEP-1998;
98US-0098821P. 02-SEP-1998; 98US-0098843P. 09-SEP-1998;
98US-0099536P. 09-SEP-1998; 98US-0099596P. 09-SEP-1998;
98US-0099598P. 09-SEP-1998; 98US-0099602P. 09-SEP-1998;
98US-0099642P. 10-SEP-1998; 98US-0099741P. 10-SEP-1998;
98US-0099754P. 10-SEP-1998; 98US-0099763P. 10-SEP-1998;
98US-0099792P. 10-SEP-1998; 98US-0099808P. 10-SEP-1998;
98US-0099812P. 10-SEP-1998; 98US-0099815P. 10-SEP-1998;
98US-0099816P. 15-SEP-1998; 98US-0100385P. 15-SEP-1998;
98US-0100388P. 15-SEP-1998; 98US-0100390P. 16-SEP-1998;
98US-0100584P. 16-SEP-1998; 98US-0100627P. 16-SEP-1998;
98US-0100661P. 16-SEP-1998; 98US-0100662P. 16-SEP-1998;
98US-0100664P. 17-SEP-1998; 98US-0100683P. 17-SEP-1998;
98US-0100684P. 17-SEP-1998; 98US-0100710P. 17-SEP-1998;
98US-0100711P. 17-SEP-1998; 98US-0100919P. 17-SEP-1998;
98US-0100930P. 18-SEP-1998; 98US-0100848P. 18-SEP-1998;
98US-0100849P. 18-SEP-1998; 98US-0101014P. 18-SEP-1998;
98US-0101068P. 18-SEP-1998; 98US-0101071P. 22-SEP-1998;
98US-0101279P. 23-SEP-1998; 98US-0101471P. 23-SEP-1998;
98US-0101472P. 23-SEP-1998; 98US-0101474P. 23-SEP-1998;
98US-0101475P. 23-SEP-1998; 98US-0101476P. 23-SEP-1998;
98US-0101477P. 23-SEP-1998; 98US-0101479P. 24-SEP-1998;
98US-0101738P. 24-SEP-1998; 98US-0101741P. 24-SEP-1998;
98US-0101743P. 24-SEP-1998; 98US-0101915P. 24-SEP-1998;
98US-0101916P. 29-SEP-1998; 98US-0102207P. 29-SEP-1998;
98US-0102240P. 29-SEP-1998; 98US-0102307P. 29-SEP-1998;
98US-0102330P. 29-SEP-1998; 98US-0102331P. 30-SEP-1998;
98US-0102484P. 30-SEP-1998; 98US-0102487P. 30-SEP-1998;

98US-0102570P. 30-SEP-1998; 98US-0102571P. 01-OCT-1998;
 98US-0102684P. 01-OCT-1998; 98US-0102687P. 02-OCT-1998;
 98US-0102965P. 06-OCT-1998; 98US-0103258P. 06-OCT-1998;
 98US-0103449P. 07-OCT-1998; 98US-0103314P. 07-OCT-1998;
 98US-0103315P. 07-OCT-1998; 98US-0103328P. 07-OCT-1998;
 98US-0103395P. 07-OCT-1998; 98US-0103396P. 07-OCT-1998;
 98US-0103401P. 08-OCT-1998; 98US-0103633P. 08-OCT-1998;
 98US-0103678P. 08-OCT-1998; 98US-0103679P. 08-OCT-1998;
 98US-0103711P. 14-OCT-1998; 98US-0104257P. 20-OCT-1998;
 98US-0104987P. 20-OCT-1998; 98US-0105000P. 20-OCT-1998;
 98US-0105002P. 21-OCT-1998; 98US-0105104P. 22-OCT-1998;
 98US-0105169P. 22-OCT-1998; 98US-0105266P. 26-OCT-1998;
 98US-0105693P. 26-OCT-1998; 98US-0105694P. 27-OCT-1998;
 98US-0105807P. 27-OCT-1998; 98US-0105881P. 27-OCT-1998;
 98US-0105882P. 27-OCT-1998; 98US-0106062P. 28-OCT-1998;
 98US-0106023P. 28-OCT-1998; 98US-0106029P. 28-OCT-1998;
 98US-0106030P. 28-OCT-1998; 98US-0106032P. 28-OCT-1998;
 98US-0106033P. 28-OCT-1998; 98US-0106178P. 29-OCT-1998;
 98US-0106248P. 29-OCT-1998; 98US-0106384P. 29-OCT-1998;
 98US-0108500P. 30-OCT-1998; 98US-0106464P. 03-NOV-1998;
 98US-0106856P. 03-NOV-1998; 98US-0106902P. 03-NOV-1998;
 98US-0106905P. 03-NOV-1998; 98US-0106919P. 03-NOV-1998;
 98US-0106932P. 03-NOV-1998; 98US-0106934P. 10-NOV-1998;
 98US-0107783P. 17-NOV-1998; 98US-0108775P. 17-NOV-1998;
 98US-0108779P. 17-NOV-1998; 98US-0108787P. 17-NOV-1998;
 98US-0108788P. 17-NOV-1998; 98US-0108801P. 17-NOV-1998;
 98US-0108802P. 17-NOV-1998; 98US-0108806P. 17-NOV-1998;
 98US-0108807P. 17-NOV-1998; 98US-0108867P. 17-NOV-1998;
 98US-0108925P. 18-NOV-1998; 98US-0108848P. 18-NOV-1998;
 98US-0108849P. 18-NOV-1998; 98US-0108850P. 18-NOV-1998;
 98US-0108851P. 18-NOV-1998; 98US-0108852P. 18-NOV-1998;
 98US-0108858P. 18-NOV-1998; 98US-0108904P; Assignee: (GETH)
 GENENTECH INC; Cross Reference: WPI; 2000-237871/20. P-PSDB;
 AAY99346; Patent Format: Claim 2; Fig 13; 773pp; English.

COMMENT AAA37022 to AAA37144 encode the new isolated human transmembrane,
 receptor or secreted PRO polypeptides given in AAY99340 to AAY99462.
 The transmembrane and receptor PRO proteins can be used for
 screening of potential peptide or small molecule inhibitors of the
 relevant receptor/ligand interactions. The polypeptides and
 nucleotide sequences encoding then have various industrial
 applications, including uses as pharmaceutical and diagnostic
 agents. AAA37145 to AAA37330 represent PCR primers and
 hybridisation probes used in the isolation of the PRO polypeptides
 from the present invention

FEATURES Location/Qualifiers
 BASE COUNT 127 a 111 c 120 g 135 t
 ORIGIN

486 100 0.0

BC021104 Homo sapiens apelin, AGTRL1 ligand, mRNA (cDNA clone MGC:31846
 IMAGE:4586949), complete cds. 2673 bp,
 mRNA, linear, PRI 30-JUN-2004

ACCESSION BC021104
 VERSION BC021104.1 GI:18088893
 KEYWORDS MGC.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 2673)

AUTHORS Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,
Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
Abramson,R.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J.,
McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
Villalón,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
Fahey,J., Helton,E., Kettelman,M., Madan,A., Rodrigues,S.,
Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,
Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smailus,D.E.,
Schnierch,A., Schein,J.E., Jones,S.J. and Marra,M.A.

TITLE Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

REFERENCE 2 (bases 1 to 2673)

AUTHORS Strausberg,R.

TITLE Direct Submission

JOURNAL Submitted (03-JAN-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA

REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>

COMMENT Contact: MGC help desk

Email: cgapbs-r@mail.nih.gov

Tissue Procurement: DCTD/DTP

cDNA Library Preparation: Rubin Laboratory

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Genome Sequence Centre,

BC Cancer Agency, Vancouver, BC, Canada

info@bcgsc.bc.ca

Steve Jones, Sarah Barber, Mabel Brown-John, Yaron Butterfield,
Andy Chan, Steve S. Chand, William Chow, Alison Cloutier, Ruth
Featherstone, Malachi Griffith, Obi Griffith, Ran Guin, Nancy Liao,
Kim MacDonald, Amara Masson, Mike R. Mayo, Josh Moran, Ryan Morin,
Teika Olson, Diana Palmquist, Anca Petrescu, Anna Liisa Prahbu,
Parvaneh Saeedi, JR Santos, Angelique Schnierch, Ursula Skalska,
Duane Smailus, Jeff Stott, Miranda Tsai, George Yang, Jacquie
Schein, Asim Siddiqui, Rob Holt, Marco Marra.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>

Series: IRAL Plate: 40 Row: f Column: 18

This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 21314667.

FEATURES Location/Qualifiers

source

1..2673

/organism="Homo sapiens"

```

        /mol_type="mRNA"
        /db_xref="taxon:9606"
        /clone="MGC:31846 IMAGE:4586949"
        /tissue_type="Kidney, renal cell adenocarcinoma"
        /clone_lib="NIH_MGC_14"
        /lab_host="DH10B-R"
        /note="Vector: pOTB7"
gene      1..2673
        /gene="APLN"
        /note="synonyms: XNPEP2, apelin"
        /db_xref="LocusID:8862"
        /db_xref="MIM:300297"
CDS       308..541
        /gene="APLN"
        /codon_start=1
        /product="apelin, preproprotein"
        /protein_id="AAH21104.2"
        /db_xref="GI:45946592"
        /db_xref="LocusID:8862"
        /db_xref="MIM:300297"

```

BASE COUNT
ORIGIN

468 100 0.0

P_AAX235184 Human kidney aminopeptidase P genomic DNA fragment 2. 998 bp,
DNA, PAT 23-JUN-1999

ACCESSION P_AAX23518

KEYWORDS GENESEQ; Aminopeptidase; human; AmP; gene therapy; treatment;
AmP-deficiency; prenatal diagnosis; angioedema; antihypertensive
agent; atherosclerosis; arterial stenosis; industrial protein feed;
malabsorption syndrome; proteinaceous waste degradation; additive;
immunohistochemistry; patent; patentdb (v200414, 01-JUL-2004).

SOURCE Homo sapiens.

ORGANISM Homo sapiens.

REFERENCE 1 (bases 1 to 49998)

AUTHORS Ryan, J.W., Sprinkle, T.J.C., Venema, R.C.

TITLE Nucleic acid encoding human aminopeptidase P.

JOURNAL Patent: WO9911799-A2; Filing Date: 02-SEP-1998; 98WO-US018426;
Publication Date: 11-MAR-1999; Priority: 02-SEP-1997;
97US-0057854P; Assignee: (MEDI-) MEDICAL COLLEGE GEORGIA RES INST;
Cross Reference: WPI; 1999-205193/17; Patent Format: Claim 13; Page
109-139; 201pp; English.

COMMENT This invention describes the isolation of a novel human
aminopeptidase P (AmP). This protein is used to produce recombinant
AmP and can be used for gene therapy for treating AmP-deficiency
conditions. Its fragments are used as primers and probes to
identify patients with homozygous and heterozygous AmP deficiency,
including prenatal diagnosis (patients defective in AmP are at risk
of developing angioedema if treated with angiotensin-converting
enzyme inhibitors), also as antisense inhibitors in cases of
excessive AmP expression. The product of the invention is also used
to identify AmP-expressing sequences in other animals and to
generate transgenic animals, and comparisons of genomic sequences
are used to detect mutations. AmP inhibitors are potentially useful
as antihypertensive agents and to prevent or treat arterial
(re)stenosis or atherosclerosis. The structure of AmP is used to
design synthetic substrates, e.g. for use in AmP assays. AmP, which

hydrolyzes N-terminal imido bonds, can be used to degrade industrial protein feeds to free amino acids, to degrade proteinaceous wastes, as additives in enzyme formulations used to treat malabsorption syndrome and for studying its biological role. Antibodies against AmP are used in immunohistochemical methods to study AmP distribution

FEATURES Location/Qualifiers

BASE COUNT 12605 a 11725 c 11351 g 14317 t

ORIGIN

468 100 0.0

HS454M7 Human DNA sequence from clone RP3-454M7 on chromosome Xq25-26.3, complete sequence. 151152 bp, DNA, linear, PRI 05-JUN-2003

ACCESSION AL022162

VERSION AL022162.1 GI:3171881

KEYWORDS HTG.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 151152)

AUTHORS Pavitt, R.

TITLE Direct Submission

JOURNAL Submitted (05-JUN-2003) Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK. E-mail enquiries:

humquery@sanger.ac.uk Clone requests: clonerequest@sanger.ac.uk

COMMENT On Jun 2, 1998 this sequence version replaced gi:2969945.

----- Genome Center

Center: Wellcome Trust Sanger Institute

Center code: SC

Web site: <http://www.sanger.ac.uk>

Contact: humquery@sanger.ac.uk

During sequence assembly data is compared from overlapping clones. Where differences are found these are annotated as variations together with a note of the overlapping clone name. Note that the variation annotation may not be found in the sequence submission corresponding to the overlapping clone, as we submit sequences with only a small overlap as described above.

This sequence was finished as follows unless otherwise noted: all regions were either double-stranded or sequenced with an alternate chemistry or covered by high quality data (i.e., phred quality = 30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by at least one plasmid subclone or more than one M13 subclone; and the assembly was confirmed by restriction digest, except on the rare occasion of the clone being a YAC.

The following abbreviations are used to associate primary accession numbers given in the feature table with their source databases:

Em:, EMBL; Sw:, SWISSPROT; Tr:, TREMBL; Wp:, WORMPEP; Information on the WORMPEP database can be found at

http://www.sanger.ac.uk/Projects/C_elegans/wormpep This sequence was generated from part of bacterial clone contigs of human

chromosome X, constructed by the Sanger Centre Chromosome X Mapping Group. Further information can be found at

<http://www.sanger.ac.uk/HGP/ChrX>

RP3-454M7 is from the library RPCI-3 constructed by the group of

Pieter de Jong. For further details see

<http://www.chori.org/bacpac/home.htm>

VECTOR: pCYPAC2

This sequence is the entire insert of clone RP3-454M7.

```

FEATURES             Location/Qualifiers
    source             1..151152
                        /organism="Homo sapiens"
                        /mol_type="genomic DNA"
                        /db_xref="RZPD:RPCIP704M07454"
                        /db_xref="taxon:9606"
                        /chromosome="X"
                        /map="q25-26.3"
                        /clone="RP3-454M7"
                        /clone_lib="RPCI-3"
    gene               767..35998
                        /gene="OCRL1"
    mRNA               join(<767..877,1303..1392,2075..2195,2282..2443,
                        3992..4093,4621..4735,5826..5942,6041..6228,9214..9325,
                        10696..10805,12706..12841,18582..18692,19339..19504,
                        19759..19994,30444..30560,31621..31705,32328..32455,
                        33287..33398,33588..35998)
                        /gene="OCRL1"
                        /product="dJ454M7.1.1 (Lowe Oculocerebrorenal Syndrome)"
                        /note="variant 1
                        match: cDNAs: Em:M88162 Em:U57627 Em:M74161 Em:AF040094
                        match: ESTs: Em:AA368192 Em:AA704671 Em:AA515789
                        Em:AA102623 Em:AA126320 Em:T63686 Em:AA884344 Em:N92504
                        Em:AA044611 Em:AA188493 Em:AA743649 Em:AA836673 Em:R67320
                        Em:AA100629 Em:AA085500 Em:R94403 Em:AA056506 Em:AA034375
                        Em:AA142870 Em:AA150871 Em:T84251 Em:AA122020 Em:AA906612
                        Em:F07337 Em:AA628152 Em:AA878369 Em:AA640853 Em:AA189134
                        Em:AA044666 Em:AA740555 Em:R18793 Em:AA844284 Em:AA904845
                        Em:AA042798 Em:AA122019 Em:H53971 Em:W38961 Em:AA805220
                        Em:AA868822 Em:AA032176 Em:AA034374 Em:T84250 Em:N56932
                        Em:AA169401 Em:AA188849 Em:N46002 Em:AA056392 Em:H87857
                        Em:W52373 Em:AA587050 Em:AA100630 Em:T88888 Em:H27722
                        Em:AA186750 Em:R66483 Em:T28294"
                        /evidence=not_experimental
    CDS                join(<769..877,1303..1392,2075..2195,2282..2443,
                        3992..4093,4621..4735,5826..5942,6041..6228,9214..9325,
                        10696..10805,12706..12841,18582..18692,19339..19504,
                        19759..19994,27786..27809,30444..30560,31621..31705,
                        32328..32455,33287..33398,33588..33712)
                        /gene="OCRL1"
                        /codon_start=1
                        /evidence=not_experimental
                        /product="dJ454M7.1.2 (variant 2)"
                        /protein_id="CAA18150.1"
                        /db_xref="GI:3171882"
    CDS                join(<769..877,1303..1392,2075..2195,2282..2443,
                        3992..4093,4621..4735,5826..5942,6041..6228,9214..9325,
                        10696..10805,12706..12841,18582..18692,19339..19504,
                        19759..19994,30444..30560,31621..31705,32328..32455,
                        33287..33398,33588..33712)
                        /gene="OCRL1"
                        /note="variant 1"
                        /codon_start=1

```

```

/evidence=not_experimental
/product="dJ454M7.1.1 (Lowe Oculocerebrorenal Syndrome)"
/protein_id="CAA18151.1"
/db_xref="GI:4160528"
repeat_region 1586..1847
/note="MIR repeat: matches 2..262 of consensus"
repeat_region 2642..2940
/note="AluJb repeat: matches 1..302 of consensus"
repeat_region 6639..6933
/note="MER33 repeat: matches 1..323 of consensus"
repeat_region 7178..8315
/note="L1PA2 repeat: matches 5000..6146 of consensus"
repeat_region 11225..11294
/note="MER5B repeat: matches 109..178 of consensus"
repeat_region 11345..11657
/note="AluYb8 repeat: matches 1..310 of consensus"
repeat_region 11736..11797
/note="31 copies 2 mer tt 72% conserved"
repeat_region 12436..12562
/note="L2 repeat: matches 2579..2710 of consensus"
repeat_region 13276..13457
/note="AluSg/x repeat: matches 129..310 of consensus"
repeat_region 13679..13873
/note="MIR repeat: matches 5..213 of consensus"
repeat_region 14132..14206
/note="MIR repeat: matches 163..233 of consensus"
repeat_region 14207..14413
/note="MER8 repeat: matches 2..239 of consensus"
repeat_region 14414..14548
/note="MIR repeat: matches 12..163 of consensus"
repeat_region 14793..15073
/note="AluY repeat: matches 1..311 of consensus"
repeat_region 15383..15589
/note="MER3 repeat: matches 1..209 of consensus"
repeat_region 16139..16279
/note="MER5B repeat: matches 29..178 of consensus"
repeat_region 16317..16466
/note="MIR repeat: matches 52..212 of consensus"
repeat_region 16667..17000
/note="L1PA9 repeat: matches 5829..6163 of consensus"
repeat_region 17001..17301
/note="AluYb8 repeat: matches 1..302 of consensus"
repeat_region 17302..17642
/note="L1PA9 repeat: matches 5491..5829 of consensus"
repeat_region 18285..18620
/note="2 copies 168 mer 78% conserved"
repeat_region 18772..18981
/note="MIR repeat: matches 6..242 of consensus"
repeat_region 18945..19005
/note="L2 repeat: matches 2648..2702 of consensus"
repeat_region 20349..20489
/note="MIR repeat: matches 1..150 of consensus"
repeat_region 20543..20697
/note="MER5A repeat: matches 22..188 of consensus"
repeat_region 21496..21830
/note="L1MC4 repeat: matches 7477..7849 of consensus"
repeat_region 22420..22650

```

```

repeat_region /note="MER46A repeat: matches 1..236 of consensus"
22894..22965
repeat_region /note="3 copies 24 mer 83% conserved"
24309..24606
repeat_region /note="AluSx repeat: matches 1..299 of consensus"
25081..25134
repeat_region /note="27 copies 2 mer ta 70% conserved"
25168..25193
repeat_region /note="13 copies 2 mer tg 100% conserved"
25262..25301
repeat_region /note="20 copies 2 mer tc 90% conserved"
25302..25642
repeat_region /note="L2 repeat: matches 2078..2419 of consensus"
26542..26704
repeat_region /note="MIR repeat: matches 1..160 of consensus"
26822..27057
repeat_region /note="MIR repeat: matches 8..255 of consensus"
28330..28399
repeat_region /note="MIR repeat: matches 82..151 of consensus"
30715..30819
repeat_region /note="MIR repeat: matches 35..138 of consensus"
31196..31319
repeat_region /note="AluJb repeat: matches 2..125 of consensus"
37202..37675
repeat_region /note="L2 repeat: matches 1597..2041 of consensus"
37676..37990
repeat_region /note="AluJb repeat: matches 1..312 of consensus"
37991..38142
repeat_region /note="L2 repeat: matches 2041..2182 of consensus"
38143..38316
repeat_region /note="MER5A repeat: matches 3..189 of consensus"
38317..38464
repeat_region /note="L2 repeat: matches 2182..2419 of consensus"
38676..38801
repeat_region /note="MIR repeat: matches 11..134 of consensus"
38858..38984
repeat_region /note="MIR repeat: matches 123..257 of consensus"
39284..39886
repeat_region /note="L2 repeat: matches 2147..2748 of consensus"
39913..40014
repeat_region /note="MIR repeat: matches 175..262 of consensus"
40015..40311
repeat_region /note="AluSg repeat: matches 1..297 of consensus"
40312..40428
repeat_region /note="MIR repeat: matches 14..175 of consensus"
40667..40774
repeat_region /note="L2 repeat: matches 2616..2702 of consensus"
40776..41088
repeat_region /note="AluSx repeat: matches 1..305 of consensus"
41528..41936
repeat_region /note="L2 repeat: matches 2267..2709 of consensus"
42180..42713
repeat_region /note="L1MB3 repeat: matches 5584..6153 of consensus"
42714..43014
repeat_region /note="AluJb repeat: matches 1..312 of consensus"
43015..43042
repeat_region /note="L1MB3 repeat: matches 6153..6178 of consensus"

```

```

repeat_region 43197..43238
                /note="5S repeat: matches 1..42 of consensus"
repeat_region 43282..43574
                /note="L2 repeat: matches 2405..2677 of consensus"
repeat_region 45284..45741
                /note="MLT1C repeat: matches 1..466 of consensus"
repeat_region 45835..45905
                /note="L2 repeat: matches 1139..1203 of consensus"
repeat_region 45906..46207
                /note="AluSq repeat: matches 12..313 of consensus"
repeat_region 46208..46584
                /note="L2 repeat: matches 1203..1621 of consensus"
repeat_region 46714..47015
                /note="AluSg repeat: matches 1..302 of consensus"
repeat_region 47016..47159
                /note="MER58B repeat: matches 196..341 of consensus"
repeat_region 47168..47374
                /note="MER30 repeat: matches 1..230 of consensus"
repeat_region 47427..47581
                /note="MER61A repeat: matches 4..158 of consensus"
repeat_region 47611..47774
                /note="AluSx repeat: matches 12..175 of consensus"
repeat_region 48682..48987
                /note="AluY repeat: matches 1..306 of consensus"
repeat_region 49541..49678
                /note="L2 repeat: matches 1906..2046 of consensus"
repeat_region 49698..49898
                /note="MER53 repeat: matches 1..188 of consensus"
repeat_region 49909..49978
                /note="LTR19B repeat: matches 59..140 of consensus"
repeat_region 50220..50423
                /note="L2 repeat: matches 2518..2730 of consensus"
repeat_region 50421..50492
                /note="3 copies 24 mer 93% conserved"
repeat_region 50846..50915
                /note="MIR repeat: matches 48..117 of consensus"
repeat_region 50914..51068
                /note="MIR repeat: matches 34..211 of consensus"
repeat_region 51124..51292
                /note="AluSg/x repeat: matches 130..300 of consensus"
repeat_region 51517..51587
                /note="MER96 repeat: matches 105..175 of consensus"
repeat_region 52716..52853
                /note="MIR repeat: matches 68..213 of consensus"
repeat_region 52994..53224
                /note="MIR repeat: matches 2..258 of consensus"
repeat_region 54036..54154
                /note="MLT1I repeat: matches 292..410 of consensus"
repeat_region 54234..54586
                /note="MLT1A2 repeat: matches 1..373 of consensus"
repeat_region 54612..54704
                /note="MLT1J repeat: matches 106..200 of consensus"
repeat_region 54708..54755
                /note="L2 repeat: matches 2691..2738 of consensus"
repeat_region 55103..55409
                /note="AluYb8 repeat: matches 1..314 of consensus"
repeat_region 55876..56326

```

```

repeat_region 56404..56697 /note="L2 repeat: matches 2225..2658 of consensus"
repeat_region 56760..56882 /note="AluSg repeat: matches 1..292 of consensus"
repeat_region 57036..57226 /note="L2 repeat: matches 2605..2730 of consensus"
repeat_region 57448..57579 /note="MIR repeat: matches 73..262 of consensus"
repeat_region 57817..58128 /note="L1PA16 repeat: matches 6025..6157 of consensus"
repeat_region 58772..59030 /note="L2 repeat: matches 2434..2746 of consensus"
repeat_region 59040..59091 /note="MIR repeat: matches 1..262 of consensus"
repeat_region 59050..59118 /note="MIR repeat: matches 206..257 of consensus"
repeat_region 59465..59797 /note="L2 repeat: matches 2626..2729 of consensus"
repeat_region 61554..61833 /note="AluSx repeat: matches 1..301 of consensus"
repeat_region 62011..62239 /note="AluSx repeat: matches 6..286 of consensus"
repeat_region 62265..62379 /note="MIR repeat: matches 2..242 of consensus"
repeat_region 63472..63529 /note="L2 repeat: matches 2430..2545 of consensus"
repeat_region 64262..64313 /note="MIR repeat: matches 185..242 of consensus"
repeat_region 64330..64409 /note="MIR repeat: matches 92..143 of consensus"
repeat_region 64459..64631 /note="MER33 repeat: matches 241..324 of consensus"
repeat_region 64637..64862 /note="L1MA10 repeat: matches 5999..6322 of consensus"
repeat_region 65788..66082 /note="MER33 repeat: matches 5..225 of consensus"
repeat_region 66968..66991 /note="AluJo repeat: matches 6..304 of consensus"
repeat_region 67036..67653 /note="L2 repeat: matches 2470..2493 of consensus"
repeat_region 67654..67700 /note="L2 repeat: matches 1882..2511 of consensus"
repeat_region 67701..67998 /note="L1PA16 repeat: matches 4148..4193 of consensus"
repeat_region 67999..68463 /note="AluY repeat: matches 1..296 of consensus"
repeat_region 68464..68826 /note="L1PA16 repeat: matches 4193..4655 of consensus"
repeat_region 68827..70335 /note="THE1B repeat: matches 1..364 of consensus"
repeat_region 70349..70538 /note="L1PA16 repeat: matches 4655..6143 of consensus"
repeat_region 70565..70865 /note="L2 repeat: matches 1697..1895 of consensus"
repeat_region 70932..71126 /note="AluY repeat: matches 1..305 of consensus"
repeat_region /note="L1ME3 repeat: matches 5734..5939 of consensus"

```

```

repeat_region 71385..71690
                /note="AluYa5 repeat: matches 1..310 of consensus"
repeat_region 71717..72253
                /note="MLT1F repeat: matches 11..513 of consensus"
repeat_region 72615..72631
                /note="MIR repeat: matches 196..212 of consensus"
repeat_region 72632..72870
                /note="MER8 repeat: matches 1..239 of consensus"
repeat_region 72871..73028
                /note="MIR repeat: matches 45..196 of consensus"
repeat_region 73892..73979
                /note="MIR repeat: matches 59..147 of consensus"
repeat_region 74431..74484
                /note="27 copies 2 mer ca 96% conserved"
repeat_region 74436..74483
                /note="2 copies 24 mer 100% conserved"
repeat_region 74504..74671
                /note="MIR repeat: matches 2..171 of consensus"
repeat_region 75019..75185
                /note="L2 repeat: matches 2517..2704 of consensus"
repeat_region 75149..75249
                /note="MIR repeat: matches 28..137 of consensus"
repeat_region 75397..75588
                /note="MLT1A1 repeat: matches 1..194 of consensus"
repeat_region 75646..75831
                /note="MLT1A1 repeat: matches 171..365 of consensus"
repeat_region 76554..76826
                /note="AluSg1 repeat: matches 1..308 of consensus"
repeat_region 76863..76903
                /note="L2 repeat: matches 2652..2693 of consensus"
repeat_region 77089..77189
                /note="MIR repeat: matches 41..144 of consensus"
repeat_region 77359..77679
                /note="AluSx repeat: matches 1..301 of consensus"
repeat_region 78584..78722
                /note="L2 repeat: matches 2615..2750 of consensus"
repeat_region 79058..79304
                /note="MIR repeat: matches 8..262 of consensus"
repeat_region 81458..81515
                /note="MIR repeat: matches 95..154 of consensus"
repeat_region 81526..81665
                /note="L2 repeat: matches 2352..2503 of consensus"
repeat_region 81793..81843
                /note="L2 repeat: matches 2706..2750 of consensus"
repeat_region 82019..82082
                /note="MIR repeat: matches 90..153 of consensus"
repeat_region 82664..82739
                /note="L2 repeat: matches 2647..2722 of consensus"
repeat_region 82740..83045
                /note="AluSx repeat: matches 1..312 of consensus"
repeat_region 83046..83071
                /note="L2 repeat: matches 2722..2747 of consensus"
repeat_region 83813..83946
                /note="MIR repeat: matches 89..250 of consensus"
repeat_region 83904..83954
                /note="L2 repeat: matches 2648..2698 of consensus"
repeat_region 83963..84024

```

```

repeat_region 84133..84258 /note="MIR repeat: matches 77..140 of consensus"
repeat_region 84602..84697 /note="MIR repeat: matches 7..136 of consensus"
repeat_region 85012..85350 /note="MIR repeat: matches 49..135 of consensus"
repeat_region 85365..85456 /note="MLT1A2 repeat: matches 1..340 of consensus"
repeat_region 85526..85776 /note="MIR repeat: matches 33..128 of consensus"
repeat_region 85935..86011 /note="MIR repeat: matches 7..262 of consensus"
repeat_region 86101..86173 /note="MER58A repeat: matches 42..121 of consensus"
repeat_region 87299..87643 /note="MER58A repeat: matches 143..219 of consensus"
repeat_region 88003..88303 /note="AluYb8 repeat: matches 1..310 of consensus"
repeat_region 92655..92799 /note="AluSx repeat: matches 1..301 of consensus"
repeat_region 99017..99109 /note="L1MC5 repeat: matches 7720..7866 of consensus"
repeat_region 99392..99521 /note="L2 repeat: matches 2388..2488 of consensus"
repeat_region 99694..99834 /note="L2 repeat: matches 2576..2710 of consensus"
repeat_region 100051..100090 /note="L2 repeat: matches 2610..2750 of consensus"
repeat_region 100093..100400 /note="20 copies 2 mer tt 80% conserved"
repeat_region 100764..100931 /note="AluSx repeat: matches 3..312 of consensus"
repeat_region 101144..101446 /note="MER3 repeat: matches 3..207 of consensus"
repeat_region 101798..101867 /note="AluJo repeat: matches 1..292 of consensus"
repeat_region 101952..102471 /note="L2 repeat: matches 2672..2744 of consensus"
repeat_region 102850..103006 /note="MER1A repeat: matches 6..527 of consensus"
repeat_region 103007..103052 /note="MIR repeat: matches 20..168 of consensus"
repeat_region 103053..103356 /note="MLT1A1 repeat: matches 1..51 of consensus"
repeat_region 103357..103729 /note="AluSp repeat: matches 1..303 of consensus"
repeat_region 103730..103791 /note="MLT1A1 repeat: matches 51..365 of consensus"
repeat_region 103886..103998 /note="MIR repeat: matches 168..231 of consensus"
repeat_region 103996..104323 /note="MSTA repeat: matches 1..114 of consensus"
repeat_region 104372..104503 /note="MSTA repeat: matches 1..388 of consensus"
repeat_region 104594..104824 /note="AluY repeat: matches 166..297 of consensus"
repeat_region /note="MIR repeat: matches 10..259 of consensus"

```



```

repeat_region 104874..104954
                /note="L2 repeat: matches 2624..2709 of consensus"
repeat_region 105235..105332
                /note="MIR repeat: matches 47..145 of consensus"
repeat_region 107333..107459
                /note="MLT1C repeat: matches 340..466 of consensus"
repeat_region 107460..107589
                /note="L1MA7 repeat: matches 6159..6288 of consensus"
repeat_region 107590..107718
                /note="MLT1C repeat: matches 211..340 of consensus"
repeat_region 107755..108017
                /note="AluJo repeat: matches 18..277 of consensus"
repeat_region 108019..108208
                /note="MLT1C repeat: matches 1..192 of consensus"
repeat_region 108326..108922
                /note="L2 repeat: matches 2080..2710 of consensus"
repeat_region 109592..109635
                /note="22 copies 2 mer gg 75% conserved"
repeat_region 110302..110511
                /note="L1MA10 repeat: matches 5970..6317 of consensus"
repeat_region 110589..111071
                /note="L1ME1 repeat: matches 5477..5952 of consensus"
repeat_region 111077..111135
                /note="L1MB4 repeat: matches 6124..6183 of consensus"
repeat_region 111153..111414
                /note="L1MB3 repeat: matches 5909..6182 of consensus"
repeat_region 111419..111617
                /note="L1ME1 repeat: matches 5283..5487 of consensus"
repeat_region 111622..112876
                /note="L1MB8 repeat: matches 4877..6173 of consensus"
repeat_region 112873..114198
                /note="L1M4 repeat: matches 3073..4391 of consensus"
repeat_region 114206..115694
                /note="L1PA2 repeat: matches 4656..6144 of consensus"
repeat_region 115723..116219
                /note="MLT2CA repeat: matches 1..489 of consensus"
repeat_region 116220..116291
                /note="3 copies 24 mer 81% conserved"
repeat_region 116283..116348
                /note="MLT2CA repeat: matches 444..508 of consensus"
repeat_region 116377..118409
                /note="L1MEc repeat: matches 1212..2985 of consensus"
repeat_region 118410..118683
                /note="AluY repeat: matches 1..298 of consensus"
repeat_region 118684..118923
                /note="L1MEc repeat: matches 983..1212 of consensus"
repeat_region 118955..119117
                /note="MER20 repeat: matches 51..218 of consensus"
repeat_region 119118..119284
                /note="L1MEc repeat: matches 802..988 of consensus"
repeat_region 119285..119682
                /note="MLT1A1 repeat: matches 1..365 of consensus"
repeat_region 119683..119810
                /note="L1MEc repeat: matches 681..802 of consensus"
repeat_region 119830..120493
                /note="L2 repeat: matches 1734..2603 of consensus"
repeat_region 120522..120894

```

```

repeat_region    /note="MLT1B repeat: matches 1..426 of consensus"
                  120923..121042
repeat_region    /note="5 copies 24 mer 68% conserved"
                  121180..121227
repeat_region    /note="2 copies 24 mer 95% conserved"
                  121184..121227
repeat_region    /note="22 copies 2 mer gt 100% conserved"
                  122617..122772
repeat_region    /note="MER5A repeat: matches 4..188 of consensus"
                  122787..122900
repeat_region    /note="MER5B repeat: matches 91..173 of consensus"
                  122901..123193
repeat_region    /note="AluJo repeat: matches 4..298 of consensus"
                  123194..123275
repeat_region    /note="MER5B repeat: matches 1..91 of consensus"
                  123437..124087
repeat_region    /note="L2 repeat: matches 1555..2750 of consensus"
                  124164..124586
repeat_region    /note="L2 repeat: matches 57..485 of consensus"
                  125405..125535
repeat_region    /note="Charlie4a repeat: matches 369..495 of consensus"
                  125536..125695
repeat_region    /note="FRAM repeat: matches 2..161 of consensus"
                  125696..126026
repeat_region    /note="Charlie4a repeat: matches 19..369 of consensus"
                  126098..126459
repeat_region    /note="MLT1A1 repeat: matches 1..365 of consensus"
                  126630..126693
repeat_region    /note="L2 repeat: matches 2641..2704 of consensus"
                  126784..127362
repeat_region    /note="L2 repeat: matches 2176..2750 of consensus"
                  127366..127489
repeat_region    /note="MIR repeat: matches 46..185 of consensus"
                  127679..127826
repeat_region    /note="L2 repeat: matches 2552..2691 of consensus"
                  127827..128126
repeat_region    /note="AluJo repeat: matches 4..302 of consensus"
                  128127..128405
repeat_region    /note="L2 repeat: matches 2241..2552 of consensus"
                  128518..128663
repeat_region    /note="L2 repeat: matches 1873..2021 of consensus"
                  128674..129015
repeat_region    /note="MLT1A1 repeat: matches 1..358 of consensus"
                  129016..129205
repeat_region    /note="L2 repeat: matches 1672..1868 of consensus"
                  129216..129297
repeat_region    /note="L2 repeat: matches 2639..2710 of consensus"
                  129340..129554
repeat_region    /note="MIR repeat: matches 53..260 of consensus"
                  129661..129924
repeat_region    /note="MIR repeat: matches 2..261 of consensus"
                  131041..131232
repeat_region    /note="AluSg/x repeat: matches 135..292 of consensus"
                  131267..131548
repeat_region    /note="AluY repeat: matches 18..311 of consensus"
                  131743..132226
repeat_region    /note="MLT1G repeat: matches 31..496 of consensus"

```

repeat_region 132996..133294
/note="AluSx repeat: matches 1..298 of consensus"
repeat_region 133642..133701
/note="MIR repeat: matches 69..128 of consensus"
repeat_region 134184..134313
/note="L1P3 repeat: matches 5682..5809 of consensus"
repeat_region 134373..134437
/note="L1MA7 repeat: matches 6224..6288 of consensus"
repeat_region 134438..134744
/note="MER2 repeat: matches 34..345 of consensus"
repeat_region 134748..134835
/note="L1MA6 repeat: matches 6154..6241 of consensus"
repeat_region 134878..135187
/note="AluSx repeat: matches 1..310 of consensus"
repeat_region 135493..135866
/note="L1MD2 repeat: matches 5962..6340 of consensus"
repeat_region 135888..136007
/note="L1ME1 repeat: matches 6026..6135 of consensus"
repeat_region 136270..136561
/note="AluSx repeat: matches 21..312 of consensus"
repeat_region 136598..136661
/note="MIR repeat: matches 69..132 of consensus"
repeat_region 136902..137090
/note="MIR repeat: matches 12..206 of consensus"
repeat_region 137099..137227
/note="MLT1D repeat: matches 1..130 of consensus"
repeat_region 137228..137524
/note="AluSx repeat: matches 1..296 of consensus"
repeat_region 137525..137870
/note="MLT1D repeat: matches 130..471 of consensus"
repeat_region 137893..138056
/note="AluJo repeat: matches 123..301 of consensus"
repeat_region 138057..138345
/note="AluSx repeat: matches 5..292 of consensus"
repeat_region 138346..138472
/note="AluJo repeat: matches 1..123 of consensus"
repeat_region 138474..138539
/note="MLT1D repeat: matches 440..505 of consensus"
repeat_region 138554..138675
/note="L2 repeat: matches 2066..2187 of consensus"
repeat_region 138694..139033
/note="L2 repeat: matches 2362..2692 of consensus"
repeat_region 138993..139044
/note="MIR repeat: matches 210..261 of consensus"
repeat_region 139737..139807
/note="MLT1C repeat: matches 393..464 of consensus"
repeat_region 139808..139873
/note="L1PA8 repeat: matches 6097..6162 of consensus"
repeat_region 139874..140272
/note="MLT1C repeat: matches 1..393 of consensus"
repeat_region 140332..140461
/note="MER5A repeat: matches 26..189 of consensus"
repeat_region 140611..140903
/note="LTR16C repeat: matches 61..387 of consensus"
repeat_region 141410..141594
/note="MIR repeat: matches 25..210 of consensus"
repeat_region 142664..142699

/note="18 copies 2 mer to 100% conserved"
 repeat_region 142714..142995
 /note="AluSc repeat: matches 1..278 of consensus"
 repeat_region 143097..143180
 /note="L2 repeat: matches 2643..2749 of consensus"
 repeat_region 143339..143662
 /note="MLT1A1 repeat: matches 6..365 of consensus"
 repeat_region 143783..143885
 /note="L2 repeat: matches 2593..2702 of consensus"
 repeat_region 145806..145889
 /note="MIR repeat: matches 37..130 of consensus"
 repeat_region 145957..146261
 /note="AluSq repeat: matches 1..308 of consensus"
 repeat_region 146264..146376
 /note="MIR repeat: matches 117..235 of consensus"
 repeat_region 147583..147657
 /note="L2 repeat: matches 2422..2502 of consensus"
 repeat_region 147859..147978
 /note="L2 repeat: matches 2616..2750 of consensus"
 repeat_region 148013..148084
 /note="L2 repeat: matches 2636..2707 of consensus"
 repeat_region 148687..149141
 /note="LTR16B repeat: matches 1..461 of consensus"
 repeat_region 150442..151102
 /note="L2 repeat: matches 1490..2109 of consensus"

BASE COUNT
 ORIGIN

468 100 0.0

AF195953 Homo sapiens membrane-bound aminopeptidase P (XNPEP2) gene,
 complete cds. 206618 bp, DNA, linear, PRI 26-MAR-2002

ACCESSION AF195953

VERSION AF195953.2 GI:19718557

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 206618)

AUTHORS Ryan, J.W., Jin, L., Horvath, I. and Sprinkle, T.J.C.

TITLE Human membrane-bound aminopeptidase P genomic DNA

JOURNAL Unpublished

REFERENCE 2 (bases 1 to 206618)

AUTHORS Ryan, J.W., Jin, L., Horvath, I. and Sprinkle, T.J.C.

TITLE Direct Submission

JOURNAL Submitted (18-OCT-1999) Vascular Biology Center, Medical College of
 Georgia, 1120 15th Street, Augusta, GA 30912, USA

REFERENCE 3 (bases 1 to 206618)

AUTHORS Ryan, J.W., Jin, L., Horvath, I. and Sprinkle, T.J.C.

TITLE Direct Submission

JOURNAL Submitted (26-MAR-2002) Vascular Biology Center, Medical College of
 Georgia, 1120 15th Street, Augusta, GA 30912, USA

REMARK Sequence update by submitter

COMMENT On Mar 26, 2002 this sequence version replaced gi:11066156.

FEATURES Location/Qualifiers

source 1..206618

/organism="Homo sapiens"

```

        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
gene     144189..176791
        /gene="XNPEP2"
mRNA     join(144189..144502,147348..147421,149203..149313,
150445..150508,151478..151582,151837..151923,
152849..152995,155710..155811,156987..157068,
157392..157587,158401..158490,159714..159823,
160536..160613,161726..161797,164422..164482,
165754..165823,166414..166518,167248..167307,
167936..168012,172845..172934,173533..176791)
        /gene="XNPEP2"
        /product="membrane-bound aminopeptidase P"
5'UTR    144189..144453
        /gene="XNPEP2"
CDS      join(144454..144502,147348..147421,149203..149313,
150445..150508,151478..151582,151837..151923,
152849..152995,155710..155811,156987..157068,
157392..157587,158401..158490,159714..159823,
160536..160613,161726..161797,164422..164482,
165754..165823,166414..166518,167248..167307,
167936..168012,172845..172934,173533..173727)
        /gene="XNPEP2"
        /codon_start=1
        /product="membrane-bound aminopeptidase P"
        /protein_id="AAG28480.1"
        /db_xref="GI:11066157"
misc_feature 160606..160608
        /gene="XNPEP2"
        /note="putative proton shuttle; unclassified site"
misc_feature 161778..161780
        /gene="XNPEP2"
        /note="divalent metal ligand; metal-binding site"
misc_feature 164435..164437
        /gene="XNPEP2"
        /note="divalent metal ligand; metal-binding site"
misc_feature 166473..166475
        /gene="XNPEP2"
        /note="divalent metal ligand; metal-binding site"
misc_feature join(167307,167936..167937)
        /gene="XNPEP2"
        /note="divalent metal ligand; metal-binding site"
misc_feature 167977..167979
        /gene="XNPEP2"
        /note="divalent metal ligand; metal-binding site"
3'UTR    175728..176791
        /gene="XNPEP2"

BASE COUNT
ORIGIN

467 99 0.0
P_AAH14799 Human cDNA sequence SEQ ID NO:12589. 243 bp, cDNA, PAT 26-JUN-2001
ACCESSION P_AAH14799
KEYWORDS  GENSEQ; Human; primer; detection; diagnosis; antisense therapy;
gene therapy; patent; patentdb (v200414, 01-JUL-2004).
SOURCE    Homo sapiens.
ORGANISM  Homo sapiens.

```

REFERENCE 1 (bases 1 to 2243)

AUTHORS Ota,T., Isogai,T., Nishikawa,T., Hayashi,K., Saito,K.,
Yamamoto,J. Ishii,S., Sugiyama,T., Wakamatsu,A., Nagai,K.,
Otsuki,T.

TITLE Primer sets for synthesizing polynucleotides, particularly the 5602
full- length cDNAs defined in the specification, and for the
detection and/or diagnosis of the abnormality of the proteins
encoded by the full-length cDNAs.

JOURNAL Patent: EP1074617-A2; Filing Date: 28-JUL-2000; 2000EP-00116126;
Publication Date: 07-FEB-2001; Priority: 29-JUL-1999;
99JP-00248036. 27-AUG-1999; 99JP-00300253. 11-JAN-2000;
2000JP-00118776. 02-MAY-2000; 2000JP-00183767. 09-JUN-2000;
2000JP-00241899; Assignee: (HELI-) HELIX RES INST; Cross Reference:
WPI; 2001-318749/34; Patent Format: Claim 8; SEQ ID NO 12589; 2537pp
+ Sequence Listing; English.

COMMENT The present invention describes primer sets for synthesising 5602
full- length cDNAs defined in the specification. Where a primer set
comprises: (a) an oligo-dT primer and an oligonucleotide
complementary to the complementary strand of a polynucleotide which
comprises one of the 5602 nucleotide sequences defined in the
specification, where the oligonucleotide comprises at least 15
nucleotides; or (b) a combination of an oligonucleotide comprising
a sequence complementary to the complementary strand of a
polynucleotide which comprises a 5'-end sequence and an
oligonucleotide comprising a sequence complementary to a
polynucleotide which comprises a 3'-end sequence, where the
oligonucleotide comprises at least 15 nucleotides and the
combination of the 5'-end sequence/3'-end sequence is selected from
those defined in the specification. The primer sets can be used in
antisense therapy and in gene therapy. The primers are useful for
synthesising polynucleotides, particularly full-length cDNAs. The
primers are also useful for the detection and/or diagnosis of the
abnormality of the proteins encoded by the full-length cDNAs. The
primers allow obtaining of the full-length cDNAs easily without any
specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742
represent human cDNA sequences; AAB92446 to AAB95893 represent human
amino acid sequences; and AAH13629 to AAH13632 represent
oligonucleotides, all of which are used in the exemplification of
the present invention

FEATURES Location/Qualifiers
BASE COUNT 467 a 630 c 637 g 509 t
ORIGIN

467 99 0.0

AK001855 Homo sapiens cDNA FLJ10993 fis, clone PLACE1002140. 2243 bp,
mRNA, linear, PRI 30-JAN-2004

ACCESSION AK001855

VERSION AK001855.1 GI:7023382

KEYWORDS oligo capping; fis (full insert sequence).

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Ota,T., Suzuki,Y., Nishikawa,T., Otsuki,T., Sugiyama,T., Irie,R.,
Wakamatsu,A., Hayashi,K., Sato,H., Nagai,K., Kimura,K., Makita,H.,
Sekine,M., Obayashi,M., Nishi,T., Shibahara,T., Tanaka,T.,

Ishii,S., Yamamoto,J., Saito,K., Kawai,Y., Isono,Y., Nakamura,Y.,
 Nagahari,K., Murakami,K., Yasuda,T., Iwayanagi,T., Wagatsuma,M.,
 Shiratori,A., Sudo,H., Hosoiri,T., Kaku,Y., Kodaira,H., Kondo,H.,
 Sugawara,M., Takahashi,M., Kanda,K., Yokoi,T., Furuya,T.,
 Kikkawa,E., Omura,Y., Abe,K., Kamihara,K., Katsuta,N., Sato,K.,
 Tanikawa,M., Yamazaki,M., Ninomiya,K., Ishibashi,T., Yamashita,H.,
 Murakawa,K., Fujimori,K., Tanai,H., Kimata,M., Watanabe,M.,
 Hiraoka,S., Chiba,Y., Ishida,S., Ono,Y., Takiguchi,S., Watanabe,S.,
 Yosida,M., Hotuta,T., Kusano,J., Kanehori,K., Takahashi-Fujii,A.,
 Hara,H., Tanase,T., Nomura,Y., Togiya,S., Komai,F., Hara,R.,
 Takeuchi,K., Arita,M., Imose,N., Musashino,K., Yuuki,H., Oshima,A.,
 Sasaki,N., Aotsuka,S., Yoshikawa,Y., Matsunawa,H., Ichihara,T.,
 Shiohata,N., Sano,S., Moriya,S., Momiyama,H., Satoh,N., Takami,S.,
 Terashima,Y., Suzuki,O., Nakagawa,S., Senoh,A., Mizoguchi,H.,
 Goto,Y., Shimizu,F., Wakebe,H., Hishigaki,H., Watanabe,T.,
 Sugiyama,A., Takemoto,M., Kawakami,B., Yamazaki,M., Watanabe,K.,
 Kumagai,A., Itakura,S., Fukuzumi,Y., Fujimori,Y., Komiyama,M.,
 Tashiro,H., Tanigami,A., Fujiwara,T., Ono,T., Yamada,K., Fujii,Y.,
 Ozaki,K., Hirao,M., Ohmori,Y., Kawabata,A., Hikiji,T., Kobatake,N.,
 Inagaki,H., Ikema,Y., Okamoto,S., Okitani,R., Kawakami,T.,
 Noguchi,S., Itoh,T., Shigeta,K., Senba,T., Matsumura,K.,
 Nakajima,Y., Mizuno,T., Morinaga,M., Sasaki,M., Togashi,T.,
 Oyama,M., Hata,H., Watanabe,M., Komatsu,T., Mizushima-Sugano,J.,
 Satoh,T., Shirai,Y., Takahashi,Y., Nakagawa,K., Okumura,K.,
 Nagase,T., Nomura,N., Kikuchi,H., Masuho,Y., Yamashita,R.,
 Nakai,K., Yada,T., Nakamura,Y., Ohara,O., Isogai,T. and Sugano,S.

TITLE Complete sequencing and characterization of 21,243 full-length
 human cDNAs

JOURNAL Nat. Genet. 36 (1), 40-45 (2004)

PUBMED 14702039

REFERENCE 2

AUTHORS Isogai,T., Ota,T., Hayashi,K., Sugiyama,T., Otsuki,T., Suzuki,Y.,
 Nishikawa,T., Nagai,K., Sugano,S., Takahashi-Fujii,A., Hara,H.,
 Tanase,T., Nomura,Y., Togiya,S., Komai,F., Hara,R., Takeuchi,K.,
 Arita,M., Nabekura,T., Ishii,S., Kawai,Y., Saito,K., Yamamoto,J.,
 Wakamatsu,A., Nakamura,Y., Nagahari,K., Masuho,Y. and Oshima,A.

TITLE NEDO human cDNA sequencing project

JOURNAL Unpublished

REFERENCE 3 (bases 1 to 2243)

AUTHORS Isogai,T. and Otsuki,T.

TITLE Direct Submission

JOURNAL Submitted (16-FEB-2000) Takao Isogai, Helix Research Institute,
 Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan
 (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)

COMMENT NEDO human cDNA sequencing project supported by Ministry of
 International Trade and Industry of Japan; cDNA full insert
 sequencing: Research Association for Biotechnology; cDNA library
 construction, 5'- & 3'-end one pass sequencing and clone selection:
 Helix Research Institute (supported by Japan Key Technology Center
 etc.) and Department of Virology, Institute of Medical Science,
 University of Tokyo.

FEATURES Location/Qualifiers

source

1..2243

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="PLACE1002140"

```

        /tissue_type="placenta"
        /clone_lib="PLACE1"
        /note="cloning vector: pME18SFL3"
CDS      6..374
        /note="unnamed protein product"
        /codon_start=1
        /protein_id="BAA91944.1"
        /db_xref="GI:7023383"

BASE COUNT
ORIGIN

449  98  0.0
AX332625      Sequence 3134 from Patent WO0194629. 458 bp,
              DNA, linear, PAT 09-JAN-2002
ACCESSION    AX332625
VERSION      AX332625.1  GI:18123259
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Young,P.E., Augustus,M., Carter,K.C., Ebner,R., Endress,G.,
              Horrigan,S., Soppet,D.R. and Weaver,Z.
TITLE        Cancer gene determination and therapeutic screening using signature
              gene sets
JOURNAL      Patent: WO 0194629-A 3134 13-DEC-2001;
              Avalon Pharmaceuticals (US)
FEATURES
              Location/Qualifiers
source       1..458
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

BASE COUNT
ORIGIN

449  98  0.0
AX332852      Sequence 3361 from Patent WO0194629. 458 bp,
              DNA, linear, PAT 09-JAN-2002
ACCESSION    AX332852
VERSION      AX332852.1  GI:18123486
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Young,P.E., Augustus,M., Carter,K.C., Ebner,R., Endress,G.,
              Horrigan,S., Soppet,D.R. and Weaver,Z.
TITLE        Cancer gene determination and therapeutic screening using signature
              gene sets
JOURNAL      Patent: WO 0194629-A 3361 13-DEC-2001;
              Avalon Pharmaceuticals (US)
FEATURES
              Location/Qualifiers
source       1..458
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"

```


/db_xref="taxon:9606"

BASE COUNT
ORIGIN

Dayhoff Protein Database (Rel 78, Mar 2004)

P_AAB87540 Human PRO831 - Homo sapiens.

Length: 73 aa

Accession: P_AAB87540;

Species: Homo sapiens.

Keywords: Human; PRO protein; mapping; patent; GENESEQ patentdb.

Patent number: WO200116318-A2.

Publication date: 08-MAR-2001.

Filing date: 24-AUG-2000; 2000WO-US023328.

Priority: 01-SEP-1999; 99WO-US020111. 15-SEP-1999; 99WO-US021090.

07-DEC-1999; 99US-0169495P. 09-DEC-1999; 99US-0170262P.

11-JAN-2000; 2000US-0175481P. 18-FEB-2000; 2000WO-US004341.

18-FEB-2000; 2000WO-US004342. 22-FEB-2000; 2000WO-US004414.

01-MAR-2000; 2000WO-US005601. 03-MAR-2000; 2000US-0187202P.

21-MAR-2000; 2000US-0191007P. 30-MAR-2000; 2000WO-US008439.

25-APR-2000; 2000US-0199397P. 22-MAY-2000; 2000WO-US014042.

05-JUN-2000; 2000US-0209832P.

Assignee: (GETH) GENENTECH INC.

Inventors: Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi CJ, Gurney AL, Watanabe CK, Wood WI;

Cross reference: WPI; 2001-183260/18. N-PSDB; AAF92072.

Title: Eighty four nucleic acids encoding PRO polypeptides, useful in molecular biology, including use as hybridization probes, and in chromosome and gene mapping.

Patent format: Claim 12; Fig 30; 278pp; English.

Comment: The present sequence is a human PRO polypeptide (secreted and transmembrane). The PRO protein, and PRO agonists, PRO antagonists or anti-PRO antibodies are useful for preparation of a medicament useful in the treatment of a condition which is responsive to the PRO protein, agonists, antagonists or anti-PRO antibodies. The PRO protein may also be employed as molecular weight markers for protein electrophoresis. The PRO coding sequence has applications in molecular biology, including use as hybridisation probes, and in chromosome and gene mapping

Database: GENESEQ patent database (v200414, 01-JUL-2004).

P_AAY99346 Human PRO831 (UNQ471) amino acid sequence SEQ ID NO:22 - Homo sapiens.

Length: 73 aa

Accession: P_AAY99346;

Species: Homo sapiens.

Keywords: Human; PRO polypeptide; membrane bound protein; receptor; diagnosis; transmembrane; secretion; immunoadhesion; pharmaceutical; screening; patent; GENESEQ patentdb.

Patent number: WO200012708-A2.

Publication date: 09-MAR-2000.

Filing date: 01-SEP-1999; 99WO-US020111.

Priority: 01-SEP-1998; 98US-0098716P. 01-SEP-1998; 98US-0098749P.

01-SEP-1998; 98US-0098750P. 18-NOV-1998; 98US-0108858P. 18-NOV-1998;

98US-0108904P. plus 119 more dates.

Assignee: (GETH) GENENTECH INC.

Inventors: Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;

Cross reference: WPI; 2000-237871/20. N-PSDB; AAA37028.

Title: New mammalian DNA sequences encoding transmembrane, receptor or secreted PRO polypeptides, useful for screening of potential peptide or small molecule inhibitors of the relevant

receptor/ligand interactions.

Patent format: Claim 12; Fig 14; 773pp; English.

Comment: AAA37022 to AAA37144 encode the new isolated human transmembrane, receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The transmembrane and receptor PRO proteins can be used for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interactions. The polypeptides and nucleotide sequences encoding then have various industrial applications, including uses as pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent PCR primers and hybridisation probes used in the isolation of the PRO polypeptides from the present invention

Database: GENESQ patent database (v200414, 01-JUL-2004).